Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

6/30/2022 Pharmaceutical Drug Production in Russia (May 2022)

In January–May 2022, Russian manufacturers produced 311.1 billion rubles’ worth of pharmaceutical drugs (manufacturer’s prices, VAT included), more than 30% up from January–May 2021. In physical terms, the production volume was 1.8 billion packages, up 5.6% from January–May 2021. If calculated in minimum dosage units (MDUs), the manufacture was 33.5 billion MDUs (up 2.7%).

6/29/2022 Database Update: Audit of Veterinary Drug Retail Sales in Russia (May 2022)

From January to May 2022, the offline sales of veterinary drugs in the Russian retail market were 9.1 billion RUB (retail prices, VAT included), down 0.2% from January–May 2021, which means that the market is stagnating, pressured by the online segment. In physical terms, the volume was 56.6 million minimum dosage units (MDU), down 18.4% in MDUs.

6/20/2022 Study by RNC Pharma and Medvestnik: One-Third of Russian Doctors Think That OMI Covers 50% of Actual Costs

According to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors, 88% of Russian doctors do not think that the current obligatory medical insurance (OMI) plans cover the actual expenses, with their opinions varying slightly on how much the plans do cover. For example, one-third of the respondents (32.7%) believe that the plans cover at best 50%. The second most popular opinion (25.6%) was “from 50 to 60%.”

6/17/2022 Study by RNC Pharma and Medvestnik: 4% of Russian Doctors Would Not Want More Time for Patients

Various patient organizations have repeatedly said that a standard doctor’s appointment should be longer. At the same time, 59.2% of Russian doctors would spend this additional time for “physical examinations and direct questioning”, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors.

6/9/2022 Import of Veterinary Drugs and Feed Supplements to Russia (April 2022)

In January–April 2022, Russia imported 12.4 billion rubles’ worth of veterinary drugs (customs clearance and VAT included), down 3.6% from the same period in 2021. As for feed supplements, the import volume was 15.5 billion rubles, up 23.4% from January–April 2021.

All news [322]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.